ADC Therapeutics makes two executive appointments

Sunday 6 November 2022
ADC Therapeutics SA
Appointee name
Kristen Harrington-Smith and Peter Graham


ADC Therapeutics SA of Switzerland has added two experienced biopharmaceutical executives to its leadership team as it advances its antibody-drug conjugate (ADC) drugs for cancer. Kristen Harrington-Smith has been appointed chief commercial officer and Peter Graham, chief legal officer.

Ms Harrington-Smith was most recently chief commercial officer at ImmunoGen Inc, one of the earliest ADC drug developers. Prior to this, she led Novartis’ haematology unit in the US where she led teams responsible for a portfolio of therapies in both malignant and non-malignant haematologic diseases.

Mr Graham, a legal expert, was previously general counsel and chief compliance officer at Antares Pharma Inc prior to its acquisition by Halozyme Therapeutics Inc in May.

ADC Therapeutics announced the appointments on 1 November 2022.

Copyright 2022 Evernow Publishing Ltd